Peptide / HGH

Bpc 157

  • CAS 137525-51-0
  • Formula C62H98N16O22
  • Half-life Estimated 4 hours
Chemical structure of Bpc 157

Clinical Notes

Mechanism, kinetics, and protocol-relevant pharmacology — reviewed by the editorial pharmacology lead.

Pentadecapeptide fragment of a human gastric juice protein (Body Protection Compound). Mechanism of action is incompletely characterised — documented effects include VEGFR-2 upregulation, NO-pathway modulation, and acceleration of tendon fibroblast proliferation in animal models. Human efficacy data is limited to case-series and off-label clinical reports; rigorous RCT data does not yet exist. Clinical picture consistent across anecdotal reports: accelerated soft-tissue healing (tendon, ligament) at 250–500 mcg/day subcutaneous; measurable effect on GI integrity (gastritis, inflammatory bowel reports). Site-specific subcutaneous injection close to the injury location is the empirical standard. Shelf-life post-reconstitution with bacteriostatic water is 4–6 weeks refrigerated. No documented side-effect profile at standard doses.

Chemical Identity

CAS Number 137525-51-0
IUPAC Name L-Valyl-L-lysyl-L-lysylglycyl-L-alanylglycyl-L-seryl-L-threonyl-L-prolyl-L-cysteinylglycylglycyl-L-lysyl-L-leucine (pentadecapeptide BPC-157)
Molecular Formula C62H98N16O22
Molecular Weight 1419.53 g/mol
Melting Point N/A (peptide) °C
Solubility Soluble in water
Half-life Estimated 4 hours

Pharmacological Profile

Aromatisation None
Hepatotoxicity None

Known trade names

  • BPC-157
  • Body Protection Compound

Cycles using this compound

External references

Data sourced from peer-reviewed pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only — not medical advice.